--- title: "Eloxx Pharmaceuticals files NT 10-K, cannot fund audit and expects going" url: "https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-04-01" section: "Distress" tickers: "NASDAQ:ELOX" source: "https://www.sec.gov/Archives/edgar/data/1035354/000110465925030543/tm2511064d1_nt10k.htm" summary: "The late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic report" --- By the aibio.space news desk. Sources - [Eloxx Pharmaceuticals, Inc. Form NT 10-K filed April 1, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1035354/000110465925030543/tm2511064d1_nt10k.htm) [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/) 2025-04-01 # Eloxx Pharmaceuticals files NT 10-K, cannot fund audit and expects going concern doubt Tickers [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/) The late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed. ## Key facts - **Company**: Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) - **News type**: Distress - **Primary source**: [Eloxx Pharmaceuticals, Inc. Form NT 10-K filed April 1, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1035354/000110465925030543/tm2511064d1_nt10k.htm) *An aerial view of the Capitol and its grounds. CC0, via rawpixel. The picture shows the field, not the companies named.* Eloxx Pharmaceuticals, Inc. (Nasdaq: [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)) said on April 1, 2025 that it cannot file its annual report for 2024 on time because it cannot allocate the money needed to engage its independent public accounting firm for the audit. The company disclosed the late filing in a [Form 12b-25 (NT 10-K) filed April 1, 2025](https://www.sec.gov/Archives/edgar/data/1035354/000110465925030543/tm2511064d1_nt10k.htm). It also expects to report cash and cash equivalents of $0.1 million as of December 31, 2024, and expects the annual report to raise doubt about its ability to keep operating. ## What the filing says Form NT 10-K is the notice a company files when it cannot complete its Form 10-K, the annual report, by the due date. Eloxx's notice covers the annual report for the year ended December 31, 2024. The company says it is currently unable to allocate the financial resources needed to engage its independent public accounting firm to audit the consolidated financial statements for that year. It says it cannot predict when the audit of the 2024 financial statements will be completed, or when it will file the Form 10-K. The notice describes the problem as a continuing one. It points back to the Form 12b-25 it filed on April 1, 2024, when it could not file its annual report for the year ended December 31, 2023 for the same reason. The company says those financial constraints are ongoing. ## Reports still unfiled In Part IV, Eloxx answered no when asked whether all other periodic reports required during the preceding 12 months had been filed. It lists four reports that are outstanding: the Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, June 30, 2024 and March 31, 2024, and the Annual Report on Form 10-K for the fiscal year ended December 31, 2023. ## Cash and going concern Eloxx expects to report cash and cash equivalents of $0.1 million as of December 31, 2024. The filing compares that with $1.1 million as of December 31, 2023 and $4.8 million as of September 30, 2023. The company also anticipates a significant increase in its net loss and accumulated deficit for 2024 compared with 2023. A going concern warning is a statement that a company may not be able to keep operating. Management anticipates disclosing in the Form 10-K substantial doubt about Eloxx's ability to continue as a going concern. The reason it gives is that the company does not currently have sufficient cash resources to support its planned operations for at least 12 months from the expected issuance date of the 2024 financial statements. The notice says this information is preliminary and subject to change. It adds that actual results may differ from the estimates and are subject to completion of the audit of the 2023 financial statements by the company's independent registered public accounting firm. ## About the company The company lists its address as P.O. Box 274, Arlington, MA 02476. Its annual report on Form 10-K filed March 31, 2023 names ELX-02 as its lead product candidate. Among the risks it listed there were its ability to obtain the capital to fund operations, its ability to obtain adequate financing through product licensing, public or private equity or debt financing or otherwise, and its dependence on ELX-02. ## Who is involved Sumit Aggarwal, President and Chief Executive Officer, signed the notice and is the named contact for questions about it. The notice carries a forward-looking statements section covering the timing and ability of the Form 10-K filing, expected results for the full year and the anticipated disclosure of doubt about its ability to continue. It says actual results may differ because of the risk factors in the company's filings with the SEC. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ELOX Eloxx Pharmaceuticals, Inc. NASDAQ ยท United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eloxx Pharmaceuticals files NT 10-K, cannot fund audit and expects going", 2025-04-01, https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/